Skip to main content

Table 3 Treatment regimens main results of all included studies

From: Efficacy and safety of proton beam therapy for rhabdomyosarcoma: a systematic review and meta-analysis

References

Surgery n (%)

Chemotherapy n (%)

Beam-delivery

Median total dose (Gy RBE)

Fractions (n)

Dose/fraction

GyRBE

Ladra et al. [13]

NR

54 (100%)

18 (31.6%)c; 18 (31.5%)f; 16 (28.1%)e; 3 (5.3%)h; 2 (3.5%)d

Passive scanning

50.4

(36.0–50.4)

NR

NR

Indelicato et al. [14]

NR

30 (100%)e/h

Passive scanning

45

25

1.8

Ludmir et al. [15]

1 (2.2%)

46 (100%)

21 (45.7%)f; 10 (21.7%)e; 7 (15.2%)o; 5 (10.9%)h; 3 (6.5%)g

Passive scanning

Active scanning

50.4

(36.0–50.8)

28

1.8–2.0

Bradley et al. [16]

1 (4.2%)

24 (100%)

15 (62.5%)h; 8 (33.3%)f; 1 (4.2%)i

Passive scanning

50.4

(41.4–59.4)

28

1.8

Indelicato et al. [17]

14 (45.2%)

31 (100%)

19 (61.3%)a; 12 (38.7%)b

Passive scanning

50.4

(36.0–59.4)

28

1.8

Buszek et al. [18]

60 (63.8%)

94 (100%)

51 (31.6%)f; 15 (31.5%)e; 10 (28.1%)g; 9 (5.3%)a; 6 (3.5%)0; 3 (3.5%)c

Passive scanning

Active scanning

50.4

(36.0–50.8)

28

1.8–2.0

Parekh et al. [19]

20 (54.1%)

37 (100%)

18 (48.7%)a; 17 (45.9%)b; 2 (5.4%)o

Passive scanning

50.4

(36.0–55.8)

28

1.8

Mizumoto et al. [20]

41 (74.5%)

53 (96.4%)NR

NR

50.4

(36.0–60.0)

NR

NR

Suzuki et al. [21]

21 (43.8%)

46 (95.8%)

40 (83.3%)j; 6 (12.5%)k

NR

50.4

(41.4–59.4)

NR

NR

Leiser et al. [22]

55 (66.3%)

83 (100%)

59 (71.1%)l; 14 (16.9%)a; 5 (6.0%)m; 3 (3.6%)f; 1 (1.2%)c; 1 (1.2%)n

Active scanning

54

(41.4–64.8)

30

1.8–2.0

Weber et al. [23]

NR

39 (100%)

28 (71.8%)l; 5 (12.8%)a; 3 (7.7%)b; 3 (7.7%)m

Active scanning

54

(50.4–55.8)

30

1.8–2.0

  1. EpSSG European Pediatric Soft Tissue Sarcoma Study Group, COG Children’s Oncology Group, NR no reported, RMS Rhabdomyosarcoma, CWS Cooperative Weichteilsarkom Studies, MSKCC Memorial Sloan Kettering Cancer Center, RBE Relative Biologic Effectiveness
  2. aEpSSG regimens; b: COG regimens; c: COG-D9803; d: D9602; e: COG-ARST0331; f: COG-ARST0531; g: COG-ARST0431; h: EpSSG 2005; i: St Jude RMS 13; j: VC (vincristine and cyclophosphamide); k: Irinotecan-containing regimen; l: CWS (2002P/ Guidance 2006/2007 HR/ Guidance 2009/ DOK IV 2004); m: SIOP-MMT-95; n: MSKCC 03,099; o: other regimens